Glasdegib is primarily used in the treatment of acute myeloid leukemia (AML), particularly in newly diagnosed patients who are not eligible for intensive chemotherapy. It works by inhibiting the Hedgehog signaling pathway, which plays a key role in cell proliferation and survival of certain cancer cells. When combined with low-dose cytarabine, it has shown to improve overall survival compared to chemotherapy alone. Its application is significant in targeted cancer therapy, offering a treatment option for patients with limited alternatives. It is taken orally, which supports outpatient treatment and improves patient convenience.